METAVIA INC (MTVA) Stock Fundamental Analysis
NASDAQ:MTVA - Nasdaq - US64132R4048 - Common Stock - Currency: USD
We assign a fundamental rating of 1 out of 10 to MTVA. MTVA was compared to 549 industry peers in the Biotechnology industry. While MTVA seems to be doing ok healthwise, there are quite some concerns on its profitability. MTVA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year MTVA has reported negative net income.
MTVA had a negative operating cash flow in the past year.
In the past 5 years MTVA always reported negative net income.
MTVA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -100.17%, MTVA is not doing good in the industry: 76.14% of the companies in the same industry are doing better.
The Return On Equity of MTVA (-192.13%) is worse than 66.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -100.17% | ||
| ROE | -192.13% | ||
| ROIC | N/A |
ROA(3y)-88.7%
ROA(5y)-125.52%
ROE(3y)-162.29%
ROE(5y)-200.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for MTVA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for MTVA has been increased compared to 1 year ago.
The number of shares outstanding for MTVA has been increased compared to 5 years ago.
There is no outstanding debt for MTVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -12.78, we must say that MTVA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MTVA (-12.78) is worse than 77.05% of its industry peers.
There is no outstanding debt for MTVA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.78 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 2.08 indicates that MTVA has no problem at all paying its short term obligations.
MTVA's Current ratio of 2.08 is on the low side compared to the rest of the industry. MTVA is outperformed by 73.95% of its industry peers.
MTVA has a Quick Ratio of 2.08. This indicates that MTVA is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.08, MTVA is not doing good in the industry: 71.95% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.08 | ||
| Quick Ratio | 2.08 |
3. Growth
3.1 Past
MTVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.87%, which is quite impressive.
EPS 1Y (TTM)72.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
MTVA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.04% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y65.26%
EPS Next 2Y29.33%
EPS Next 3Y15.99%
EPS Next 5Y-1.04%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
MTVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MTVA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MTVA's earnings are expected to grow with 15.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.33%
EPS Next 3Y15.99%
5. Dividend
5.1 Amount
MTVA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.6506
+0.01 (+1.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners3.7%
Inst Owner ChangeN/A
Ins Owners1.65%
Ins Owner Change1.57%
Market Cap15.74M
Analysts84.44
Price Target14.03 (2056.47%)
Short Float %0.48%
Short Ratio0.34
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)29.6%
Min EPS beat(2)17.77%
Max EPS beat(2)41.42%
EPS beat(4)4
Avg EPS beat(4)28.1%
Min EPS beat(4)17.77%
Max EPS beat(4)41.42%
EPS beat(8)6
Avg EPS beat(8)-6.49%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.29%
EPS NQ rev (1m)0%
EPS NQ rev (3m)27.59%
EPS NY rev (1m)0%
EPS NY rev (3m)26.97%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.64 | ||
| P/tB | 1.64 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.67
EYN/A
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0
BVpS0.4
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -100.17% | ||
| ROE | -192.13% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-88.7%
ROA(5y)-125.52%
ROE(3y)-162.29%
ROE(5y)-200.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 10.53% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.08 | ||
| Quick Ratio | 2.08 | ||
| Altman-Z | -12.78 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)291.11%
Cap/Depr(5y)174.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%85.95%
EPS Next Y65.26%
EPS Next 2Y29.33%
EPS Next 3Y15.99%
EPS Next 5Y-1.04%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-116.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-116.03%
OCF growth 3YN/A
OCF growth 5YN/A